에이치앤에스팜

비상장계속사업자

HEALTH & SAFETY PHARM

김홍기

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

에이치앤에스팜

Business Reg. No. 2158786197 · CEO 김홍기

I.Investment Overview

Target에이치앤에스팜 (2158786197)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명에이치앤에스팜
영문명HEALTH & SAFETY PHARM
대표자김홍기
사업자등록번호2158786197
법인등록번호1101115204477
설립일2013.11.06

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW377.72021437.62022469.92023459.72024478.22025
영업이익100M KRW6.42021820225.820236.220246.72025
순이익100M KRW2.920213.920220.320230.320240.42025
Item20252024202320222021
자산총계211.6억원182억원174.9억원181억원176.6억원
부채총계143.7억원112.4억원103.7억원108억원104.5억원
자본총계67.9억원69.5억원71.2억원73억원72.1억원
매출액478.2억원459.7억원469.9억원437.6억원377.7억원
영업이익6.7억원6.2억원5.8억원8억원6.4억원
순이익3,786만원3,012만원2,654만원3.9억원2.9억원

VI.Financial Ratios

FY2025 basis

1.41%

영업이익률

0.08%

순이익률

0.18%

ROA

0.56%

ROE

211.54%

부채비율

32.1%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

에이치앤에스팜 투심보고서 | Alpha Lenz